Solid Biosciences Inc. operates as a biotechnology company. The Company develops therapies and devices for the patients with duchenne muscular dystrophy. Solid Biosciences serves clients in the United States.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Solid Biosciences (SLDB US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-06-07)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-3/A | Registration statement for specified transactions by certain issuers (Amendment)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)